ALX Oncology at UBS conference: two pipeline bets near key tests
On November 17, 2026, ALX Oncology (ALXO) presented a two-pronged clinical strategy at the UBS Global Biopharma Conference, aiming to advance its lead programs, ALX2004 and evorpacept, toward registrational studies within the next year. CEO and Chief Medical Officer Jason Lettmann highlighted promising progress in both programs while acknowledging the execution risks associated with early clinical development.
Both ALX2004, an EGFR-targeted antibody-drug conjugate, and evorpacept, a CD47 inhibitor, are nearing critical clinical inflection points, with potential pathways to further development if progress continues.
ALX2004, designed and developed internally by ALX Oncology since 2021, is currently in Phase I trials involving over 35 patients across four tumor types, including lung and head and neck cancer. Participants are mostly in the fourth-line treatment setting, having undergone three prior therapies. The company aims to minimize dose-limiting toxicity, primarily attributed to the payload rather than the antibody itself. The current 4 mg/kg dose is deemed sufficient for the ongoing trials.
Meanwhile, evorpacept is being tested in ASPEN-09, a Phase II study enrolling 120 patients with HER2-positive metastatic breast cancer. Data from this study is anticipated in the second half of 2027, with the goal of identifying CD47-high patients who are most likely to benefit from the treatment. ALX Oncology's strategy for evorpacept involves selecting patients based on CD47 expression levels, aiming to optimize treatment efficacy.
ALX Oncology's financial standing is robust, with sufficient cash reserves to support funding through mid-2026 after a recent $159 million capital raise. This financial cushion allows the company to progress toward key clinical milestones. Stock performance has been strong, with the current share price at $1.025, up 2.5% from the previous close.
The stock has traded between $0.862 and $2.66 over the past year. Lettmann emphasized the company's focus on developing an ADC that keeps patients on treatment, while evorpacept's success hinges on targeting the right CD47-high population.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.